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Introduction
Despite intensive efforts, advanced breast cancer (ABC) remains an incurable disease and the role of systemic chemotherapy is mainly palliative. The anthracyclines doxorubicin and 4-epidoxorubicin (epirubicin, EPI) are considered two of the most active agents in the treatment of ABC. Although at equimolar doses, EPI appears to be as effective as doxorubicin, it probably induces a comparatively lesser degree of severe myelosuppression as well as of nausea and vomiting [1, 2] .
In vitro data suggest that resistance to daunorubicin uptake in resistant P388 mouse leukemia cell lines can be overcome by increasing the concentration of the drug [3] . Although doxorubicin demonstrates a relatively flat slope in several tumor cell lines, including breast cancer [4] , a steep slope was observed in others [5, 6] . This shape of the curve indicates that a relatively small increase in the drug dose may be crucial for maximal cell killing.
* Part of this work was presented at the 33rd ASCO meeting, Denver, CO, USA, May 1997.
The principle of dose as an important prognostic factor for survival in the adjuvant treatment of breast cancer was first recognized by Bonadonna and Valagussa [7] in a retrospective analysis of data from the first Milan trial. A few years later, Hryniuk and Bush [8] introduced the principle of dose intensity (DI) and suggested that DI strongly correlates with improved survival of patients with ABC. However, in both cases, many uncertainties and complexities regarding the methodology used to define the role of dose size and DI, particularly in retrospective analyses, have been pointed out by several investigators [9] [10] [11] .
On the basis of this information, the Hellenic Cooperative Oncology Group (HeCOG) became interested in testing the activity and toxicity of moderately high doses of EPI (110 mg/m 2 ) as monotherapy in patients with ABC. When administered as a single agent at a dose of 110-120 mg/m 2 every 3-4 weeks, EPI produces response rates similar to those achieved with combination chemotherapy, although complete response (CR) rates do not exceed 10% [12, 13] . In a series of phase II studies we have shown that the administration of EPI at this dose level was accompanied by a high incidence of grade 3 leukopenia and frequent treatment delays [14] . However, with the prophylactic use of G-CSF we were able to deliver this dosage every four or even every two weeks with minimal morbidity and an improved quality of life [15, 16] . In the latter case, the DI of EPI was doubled and the CR rate increased over those of the previous studies.
In order to exclude the possibility that this increase in CR rate occurred by chance, we performed the present randomized phase II study which was specifically designed to answer a single question: does doubling of the DI of EPI have a significant influence on the CR rate in patients with ABC? It is noteworthy that, by study design, the dose size and the cumulative dose of EPI were identical in the two arms but that the DI was doubled in the experimental arm.
Patients and methods
From January 1991 until April 1996, 167 women with ABC were enrolled in the study. Eligibility criteria included a) histologically proven advanced breast cancer, b) age > 18 years, c) measurable or evaluable disease, d) no previous chemotherapy for advanced disease or previous radiotherapy of the indicator lesion(s), unless a subsequent progression was documented, e) no clinically symptomatic brain metastases, f) a performance status (PS) < 2 of the ECOG scale, g) adequate hematological, renal and hepatic function and h) informed consent according to our institutional policy. A history of previous adjuvant chemotherapy was acceptable if this treatment had been discontinued at least one year before the patient's entry into the study. Patients with osseous metastasis as the only indicator lesion and tumoral estrogen or progesterone receptor level > 10 fmoles/mg of cytosol protein, should have shown improvement after receiving at least one hormonal treatment.
Randomization, based on a random-number list, was performed at the HeCOG Data Office in Athens. Patients were stratified according to their histories of previous adjuvant chemotherapy (no vs yes with or without an anthracycline-containing regimen) and risk category in a modified version of the one used by Cavalli et al. [17] . Risk categories were based on the following criteria: a) disease-free interval from initial radical surgery to first recurrence > 5 years with only osseous or locoregional metastases, b) disease-free interval of one to five years and an absence of visceral metastases, c) all others.
Pretreatment evaluation included a complete medical history, clinical examination, electrocardiogram, complete blood counts (CBQ, complete biochemistry, chest X-ray, bone scan and computed tomography (CT) scan, as indicated. A left ventricular ejection fraction measurement was required only for high-risk patients, i.e., those who were pretreated with an anthracycline or mitoxantrone in an adjuvant setting, those previously irradiated in the chest wall or residual breast and those with a previous history of uncomplicated or reversible cardiac disease.
Treatment consisted of EPI (110 mg/m 2 ) infused over 15 min every four (group A) or every two weeks (group B) for six cycles, filgrastim (5 ug/kg) was administered subcutaneously on days 2-12 of each cycle. Dose escalation was not allowed in this study. In case of leukopenia or thrombocytopenia, treatment was delayed until recovery to 3,500/ul and 100,000/uI, respectively. In incidences of grade 3 toxicity, the dose of EPI had to be reduced by 25%, and of grade 4 by 50% in all subsequent cycles. Anti-emetic therapy included ondansetron ± dexamethasone in all cases. Clinical examination, CBC and biochemical analysis were repeated prior to each cycle of chemotherapy. Examinations by imaging methods were repeated after the third cycle m group A and three to four weeks after the completion of chemotherapy in both groups. All patients were followed closely every three months for signs of progression. All patient charts and imaging material pertinent to treatment response and tumor progression were reviewed by two of the authors (A.A., A.K.-F.).
Standard Eastern Cooperative Oncology Group criteria were used to define measurable disease, assessable disease and response [18] . CR of bone disease was defined as remineralization of all lytic lesions documented radiologically and the disappearance of all areas of positive uptake on bone scan. PR was defined as remineralization of ^ 50% of lytic lesions with no increase in size of any lytic lesion or the appearance of new lesions. SD was defined as remineralization of less than 50% of lytic lesions and no new lesions and PD as a measurable increase in size of any lytic lesions or the appearance of new lesions. Blastic bone disease was not considered measurable and was not used to assess response. Toxicity criteria were those adopted by the WHO [19] .
For Crs, duration of response was calculated from the date when the CR was documented until the date of progression, and for PR from initiation of chemotherapy until the date of progression. Due to the relatively long follow-up of this study, we decided to also perform time to progression (TTP) and survival analysis. TTP was calculated from the initiation of treatment with EPI to the date on which progression of the disease was first documented, and survival from initiation of treatment with EPI to the date of last contact or to the date of death. Patients who were progression-free or alive at the last update were censored. Patients whose deaths were probably treatment-related were considered to have had tumor progression at the time of death. Patients who died of causes unrelated to the tumor or to the treatment were censored as though they had been disease-free at that time.
Statistical analysis
The present study was performed on the 'intent to treat' basis and thus all randomized patients were included in the analysis. The sample size was calculated on the basis of the assumption that a response rate of 35% was expected in group A and a 60% rate in group B. The 25% postulated difference in the response rate was derived from our previous phase II studies [14, 15] . For an alpha and beta level error of 0.05 and 0.20, respectively, 80 assessable patients were required per group. The total number of patients was estimated to be 170, taking into consideration a 3% withdrawal. An interim analysis was not planned for this study. Patient characteristics, tumor response rates and toxicities were compared by the x 2 -test of homogeneity [20] , while a twotailed, non-paired (-test was used to compare DI between the two treatment arms.
Stepwise logistic regression [21] was used to identify prognostic factors significant for response. Survival and TTP curves were estimated by the Kaplan-Meier method [22] , while the impact of treatments or other patient characteristics on TTP and survival was tested by the log-rank test [23] . Cox's proportional hazards model [24] was used in multivariate survival analysis to provide an overall treatment comparison with respect to TTP and survival, while adjusting for known prognostic factors. Stepwise logistic regression as well as univariate and multivariate survival analyses included the following variables: assigned treatment (four-week vs. two-week), age at the time of study entry (<58 vs. ^58 years), relapse-free interval (RFI, <12 months vs. 12-60 months vs. > 60 months), previous adjuvant chemotherapy (yes vs. no), previous adjuvant hormonotherapy (yes vs. no), previous adjuvant radiotherapy (yes vs. no), hormonotherapy for metastatic disease (yes vs. no), previous radiotherapy for metastatic disease (yes vs. no), menopausal status (pre-and penmenopausal vs postmenopausal), performance status (zero vs. one and two) existence of multiple metastases (yes vs. no) and existence of visceral metastases (yes vs. no). The estrogen receptor status was not included in the univariate analysis because of the large number of missing values. Time-dependent variables such as DI or response to EPI were also excluded from the analysis The assumption of proportionality of Cox's model was checked by using log minus log curves as well as Andersen's plots [25] , All calculations were based on two-sided alternatives. All tests were carried out using the BMDP statistical package [26] .
Results

Patient population
A total of 167 patients, 81 in group A and 86 in group B were randomized into this trial. Comparison of the two groups showed no difference with regard to patient and disease characteristics, listed in Table 1 . The majority of patients presented with a PS of zero to one and had visceral metastases. Two patients in group A and six in group B had osseous metastases only.
Compliance and response to treatment
Sixty-four patients (79%) in group A and 65 patients (76%) in group B received all six cycles of treatment ( Table 2) . Reasons for premature discontinuation of treatment in those 38 patients was progression of the disease (28 patients), toxicity (five), sudden death (one), change of treatment center (two) and voluntary withdrawal (two). The total 48 of patients required treatment delays (18 in group A and 30 in group B). In 60 (36%) patients (29 in group A and 31 in group B) the initially planned dose of EPI had to be reduced because of toxicity. Eventually, 42 (51%) patients in group A and 27 (31%) in group B completed the treatment according to the protocol. Even though the median cumulative dose of EPI was identical in the two groups (651 mg/m 2 ), the group B median DI was almost double the one in group A ( Table 2 ). The small dose variations observed in a few patients derived from preparation of the drug solution. However, two patients in group B received > 5% of the initially planned dose.
Four patients in group A and five in group B could not be evaluated for response to chemotherapy. Of these, one had metastatic disease only to the stomach so that tumor response could not be assessed, two patients continued their treatment after the first cycle in other hospitals and one refused further treatment after the first cycle. One patient discontinued her treatment after the second cycle because of myelotoxicity and was later treated with another regimen, while four patients (two in each group) died, probably of treatment-related causes. More analytically, one patient, who developed severe anemia, died suddenly after the first cycle. Two others died also after the first cycle, one of sepsis and one of irreversible cardiac failure. The latter patient had been treated six years prior to study entry with an adjuvant chemotherapy which included mitoxantrone at a total dose of 90 mg/m 2 . A week after the first course of epirubicin she was admitted to the hospital because of severe cardiopulmonary failure and died three days later. Finally, one patient died after the second cycle of a pulmonary embolism.
However, since analysis of the results in the present study was performed on the 'intent to treat' basis, all these patients were considered evaluable for response, toxicity and survival analysis.
Four patients (5%, 95% CI: 0.16%-9.84%) in group A Abbreviations: RFI -relapse-free interval (from initial operation); PS -performance status; ER -estrogen receptor; CT -chemotherapy; HT -hormonotherapy; RT -radiotherapy; AD -advanced disease. and 15 (17%, 95% CI: 8.92%-25.08%) in group B achieved a CR. This difference was statistically significant at the P = 0.011 level (Table 3) . Complete responses were mainly noticed in soft tissue disease, as expected, although the complete disappearance of hepatic, lung and osseous lesions was also seen. Nevertheless, overall response rates were similar in the two groups (49% vs. 53%, respectively, P = 0.5957). The median duration of response was 10 months (range 2.1-20.1+) in group A and 8.5 months (range 3.3-43.3+) in group B {P = 0.5130). Logistical regression analysis showed that only PS was a significant factor for response to chemotherapy. Patients with PS = 0 had a 1.55 times higher probability of response than those with PS = 1 or 2.
Toxicity
The incidence of the main adverse reactions (at their worst degree) are shown in Table 4 . There was no signifi- cant difference in any type of toxicity between the two patient groups. The most common grades 3 and 4 toxicities in group A and group B were anemia (3% vs. 8%, respectively), leukopenia (5% vs. 10%), thrombocytopenia (3% each) nausea/vomiting (6% vs. 8%), stomatitis (3% vs. 1%) and alopecia (38% vs. 39%). Also, five patients (6%) in group A and 10 (12%) in group B (P = 0.3363) required blood product transfusions. Antibiotics were administered in nine (11%) patients in group A and in 10 (12%) in group B. Moreover, 11 (14%) patients in group A and 16 (19%) in group B were hospitalized during their treatment period for various reasons. A number of patients received secondline chemotherapy after they had demonstrated disease progression. However, taxanes were administered to a similar number of women in each group (14 and 13, respectively).
Time to progression and survival
As of September 1, 1996, after a median follow-up of 25 months (range 0.43-43.3+) a total of 137 (82%) patients, 67 (83%) in group A and 70 (82%) in group B, demonstrated tumor progression and 105 (63%), 52 (64%) in group A and 53 (62%) in group B, had died. There was no significant difference in TTP or survival between the two groups. The median TTP was 7.2 months (range 0.2-35.4+) for group A and 7.4 months (range 0.4-43.3+) for group B (P = 0.2970, Figure 1) . Similarly, the median survival was 14.6 months (1-42.8+) for group A and 14.9 months (range 0.4-43.3+) for group B (P -0.4483, Figure 2 ).
In the univariate analysis of prognostic factors for TTP, the presence of multiple metastases (P -0.0017) and visceral metastases (P -0.0225) were found to be strongly associated with TTP (Table 5 ). In the proportional hazards model only the presence of multiple metastases retained its prognostic significance [P = 0.0020, exp (beta) = 1.904].
Moreover, in the univariate analysis of prognostic variables for survival, PS (P -0.0042) and the presence of multiple metastases (P -0.0353) were pointed out as significant factors predicting survival (Table 6 ). In the proportional hazards model only PS was deemed significant [P -0.0049, exp (beta) = 1.914]. Table 5 . Impact of selected variables on time to progression, using univariate analysis (n = 167). 
Discussion
The concepts of dose size and DI and their influence on response rate and survival of patients with ABC remain an area of intensive clinical investigation. According to the mathematical model of Goldie and Coldman [27] and the animal experiments of Skipper [28] , DI is important for the degree of tumor response while dose size is responsible for reducing the chance of developing resistant cells, and therefore it contributes to an increased likelihood of cure. On the other hand, cumulative dose best correlates with duration of response and survival.
In an early study a decade ago, Hortobagyi et al. [29] 
Abbreviations: RFI -relapse-free interval; CT -chemotherapy; HThormonotherapy; RT -radiotherapy; AD -advanced disease; PSperformance status; NS -not significant.
standard FAC or high-dose FAC chemotherapy, with the first three cycles to be given in a protected environment. At the third course of the high-dose FAC, the dose of doxorubicin was double, that of fluorouracil 2.5 times and that of cyclophosphamide three times the standard dose. However, there was no significant difference in the overall response rates or survival between the two groups.
In the meantime, mainly in Europe, EPI had successfully replaced doxorubicin in the FAC regimen, as demonstrated by two phase III trials [30, 31] . During the last six years, a number of randomized studies in patients with ABC have evaluated the effect of dose size or DI of EPI on response rate. EPI was administered either in combination with other drugs [13, [32] [33] [34] or as monotherapy [35, 36] . Response rates were significantly increased with the administration of higher doses in all studies looking at a dose-response relationship [13, 32- 35]. However, in all of them the dose of EPI in the 'lowdose' group could be considered below the recommended optimal dosage which is 110-120 mg/m 2 , when given as a single agent and 75 mg/m 2 when combined with other myelosuppressive drugs [2] . Interestingly, CR rates achieved by the intensified treatments were similar among studies. However, even though this finding indicates a threshold effect with optimal dosage of EPI, small nonrandomized studies [37, 38] suggest that there is a doseresponse relationship with EPI doses over 120 mg/m 2 every two or three weeks, and with G-CSF support.
The value of the study conducted by Ebbs et al. [36] , which did not demonstrate a significant increase of response rate with the higher dose of EPI, is limited by its 2 x 2 factorial design and by the small sample size. Also, it has to be mentioned that, in this study, EPI was given weekly and at a low dose. In a randomized study by Blomqvist et al. [39] , patients were allocated to receive FEC chemotherapy either every four weeks or once a week. The efficacy of the FEC regimen was greater when treatment was delivered every four weeks rather than once a week, despite identical DI.
Despite significant improvement in response rate, there was no evidence that survival was prolonged in the studies of Table 7 . However, this finding could be due simply to the fact that these studies did not have sufficient power to detect small differences in survival. At any rate, a positive correlation between increased complete response rate and survival has been reported in several other randomized trials [40, 41] and in a metaanalysis reviewing response rates and median survival [42] . In the trial conducted by Focan et al. [32] there was a significant difference in the duration of response and TTP, in favor of the intensified treatment. In the present study the median TTP was approximately seven months, similar to that observed with EPI doses greater than 90 mg/m 2 every three weeks, and the median survival was 15 months, which is within the range of 17-21 months reported in most studies [13, [32] [33] [34] . Nevertheless, definite conclusions can not be drawn about the impact of increased CR rate on survival, since the statistical limitations mentioned previously for the studies of Table 7 hold true for our study as well.
It is clear that most of the randomized trials listed in Table 7 share a serious methodological problem, that is, the concurrent evaluation of three dose parameters, dose size, cumulative dose and DI, which does not allow the reader to distinguish the impact of the individual parameters on the improvement of response rate. In Table 7 . Randomized studies evaluating the influence of epirubicin dose size and dose intensity on response rate of patients with advanced breast cancer. Results based on an interim analysis. c 25 mg orally twice a day for five days.
Abbreviations: F -fluorouracil; E -epirubicin; C -cyclophosphamide; P -prednisone; DI -planned dose intensity (mg/m 2 /weeV); NS -not significant; w -weekly.
contrast, the present study is unique because DI was the only test variable, since dose size and cumulative dose of EPI were, by study design, the same in both groups. The doubling of DI in the experimental arm was easily achieved by the use of G-CSF and according to the Norton-Simon hypothesis [43] , the treatment was intended to be given over a brief period before the development of drug resistance.
Logistic regression analysis with response as the endpoint revealed that symptomatic patients had a lower probability of responding to chemotherapy than those with PS = 0. In the trial by Canellos et al. [40] , patients with poor PS and those with liver metastases derived greater benefit from the more toxic treatment than from the less toxic monochemotherapy.
In our study, toxicity was generally mild to moderate. The low incidence of severe stomatitis in both groups resulting from the prophylactic use of G-CSF, and of nausea and vomiting, probably due to the utilization of ondansetron for the entire study population, are worth pointing out. The low incidence of total alopecia is in accord with that observed in our previous phase II studies with this dose of epirubicin and is probably due to the fact that scalp hypothermia was routinely used in most participating centers.
In conclusion, the present study has demonstrated that doubling of the DI of EPI monotherapy significantly increases the CR rate but probably has no impact on the TTP or survival of patients with ABC.
